drugset / Trial / NCT01583777

Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

NCT01583777

Phase 1 Completed 6 enrolled Acrotech Biopharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study the mass balance, pharmacokinetics (PK), and safety of belinostat following IV administration in patients with a recurrent or progressive malignancy.

Timeline

Start
2013-09
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Belinostat Small molecule 1000 mg/m2 Intravenous
Subject Belinostat Small molecule 1500 mg Intravenous

Indications

No indication recorded.